Fig. 2

![Fig. 2: Safety data including adverse event rates and laboratory abnormalities across bitopertin dose groups and placebo over the one-year treatment period are summarized.](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791769/bin/12888_2016_778_Fig2_HTML.jpg)

> Source: Yoshio Hirayasu et al. "A double-blind randomized study assessing safety and efficacy following one-year." *BMC psychiatry*, 2016. PMID: [26980460](https://pubmed.ncbi.nlm.nih.gov/26980460/)

<figure>
  <img src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791769/bin/12888_2016_778_Fig2_HTML.jpg" alt="Safety data including adverse event rates and laboratory abnormalities across bitopertin dose groups and placebo over the one-year treatment period are summarized." />
  <figcaption>Fig. 2. Safety data including adverse event rates and laboratory abnormalities across bitopertin dose groups and placebo over the one-year treatment period are summarized.<br>  Source: Yoshio Hirayasu et al. "A double-blind randomized study assessing safety and efficacy following one-year." <em>BMC psychiatry</em>, 2016. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26980460/">26980460</a></figcaption>
</figure>